Praxis Precision Medicines, Inc. PRAX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s operating cash flow?
- Praxis Precision Medicines, Inc. (PRAX) reported operating cash flow of -$86.15M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s operating cash flow changed year-over-year?
- Praxis Precision Medicines, Inc.'s operating cash flow decreased by 62.5% year-over-year, from -$53.01M to -$86.15M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s operating cash flow has grown at a 18.9% compound annual growth rate (CAGR), from -$124.55M to -$249.07M.
- What does operating cash flow mean?
- The net cash flow resulting from the company's day-to-day business activities.
- How do you interpret operating cash flow?
- Higher values indicate better operational self-sufficiency, while negative values are typical for pre-revenue clinical-stage biotechs.
- How does operating cash flow compare across companies?
- Typically negative for clinical-stage biopharmaceutical companies.